FDA Approves Roivant Therapy for Rare Autoimmune Disease Dermatomyositis
Source Summary
The FDA has approved a new medicine developed by Roivant and its subsidiary Priovant for treating dermatomyositis, a rare autoimmune disease. This marks a regulatory milestone for the company's therapeutic offering in the rare disease space.
Why it matters
FDA approval expands treatment options for patients with dermatomyositis and validates Roivant's drug development pipeline in rare autoimmune conditions.
